Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database

S. Rusconi, P. Vitiello, F. Adorni, B. Bruzzone, A. De Luca, V. Micheli, P. Meraviglia, R. Maserati, M. Di Pietro, G. Colao, G. Penco, A. Di Biagio, G. Punzi, L. Monno, M. Zazzi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Raltegravir (RAL) is the only licensed human immunodeficiency virus (HIV) integrase inhibitor. The factors associated with the virological response to RAL-containing regimens and the prevalence of integrase mutations associated with RAL failure deserve further investigation. From the Antiretroviral Resistance Cohort Analysis database, we selected triple-class-experienced subjects failing their current treatment with complete treatment history available. Selection criteria included HIV-RNA, CD4 count and HIV genotype within 3 months of RAL initiation. Factors associated with 24-week response were analysed; genotypic sensitivity scores (GSS) and weighted-GSS were evaluated. Virological response was achieved in 74.3% of 105 subjects. Mutations associated with RAL failure were detected in 12/24 subjects with an integrase genotype, with the prevalence of Q148H + G140S. Each extra unit of GSS (p 0.05, OR 2.62; 95% CI 1.00-6.87). was found to be a associated with response. Weighted-GSS had borderline statistical significance (p 0.063, OR 2.04; 95% CI 0.96-4.33) When stratifying for different cut-offs (

Original languageEnglish
Pages (from-to)936-942
Number of pages7
JournalClinical Microbiology and Infection
Volume19
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Databases
Mutation
Integrases
HIV
Integrase Inhibitors
Genotype
CD4 Lymphocyte Count
Patient Selection
Cohort Studies
History
Raltegravir Potassium
RNA

Keywords

  • Drug resistance
  • Genotype
  • human immunodeficiency virus type 1-1
  • Raltegravir
  • Virological response

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database. / Rusconi, S.; Vitiello, P.; Adorni, F.; Bruzzone, B.; De Luca, A.; Micheli, V.; Meraviglia, P.; Maserati, R.; Di Pietro, M.; Colao, G.; Penco, G.; Di Biagio, A.; Punzi, G.; Monno, L.; Zazzi, M.

In: Clinical Microbiology and Infection, Vol. 19, No. 10, 10.2013, p. 936-942.

Research output: Contribution to journalArticle

Rusconi, S, Vitiello, P, Adorni, F, Bruzzone, B, De Luca, A, Micheli, V, Meraviglia, P, Maserati, R, Di Pietro, M, Colao, G, Penco, G, Di Biagio, A, Punzi, G, Monno, L & Zazzi, M 2013, 'Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database', Clinical Microbiology and Infection, vol. 19, no. 10, pp. 936-942. https://doi.org/10.1111/1469-0691.12100
Rusconi, S. ; Vitiello, P. ; Adorni, F. ; Bruzzone, B. ; De Luca, A. ; Micheli, V. ; Meraviglia, P. ; Maserati, R. ; Di Pietro, M. ; Colao, G. ; Penco, G. ; Di Biagio, A. ; Punzi, G. ; Monno, L. ; Zazzi, M. / Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database. In: Clinical Microbiology and Infection. 2013 ; Vol. 19, No. 10. pp. 936-942.
@article{58a7be1ba67140b3abd28101ef67886c,
title = "Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database",
abstract = "Raltegravir (RAL) is the only licensed human immunodeficiency virus (HIV) integrase inhibitor. The factors associated with the virological response to RAL-containing regimens and the prevalence of integrase mutations associated with RAL failure deserve further investigation. From the Antiretroviral Resistance Cohort Analysis database, we selected triple-class-experienced subjects failing their current treatment with complete treatment history available. Selection criteria included HIV-RNA, CD4 count and HIV genotype within 3 months of RAL initiation. Factors associated with 24-week response were analysed; genotypic sensitivity scores (GSS) and weighted-GSS were evaluated. Virological response was achieved in 74.3{\%} of 105 subjects. Mutations associated with RAL failure were detected in 12/24 subjects with an integrase genotype, with the prevalence of Q148H + G140S. Each extra unit of GSS (p 0.05, OR 2.62; 95{\%} CI 1.00-6.87). was found to be a associated with response. Weighted-GSS had borderline statistical significance (p 0.063, OR 2.04; 95{\%} CI 0.96-4.33) When stratifying for different cut-offs (",
keywords = "Drug resistance, Genotype, human immunodeficiency virus type 1-1, Raltegravir, Virological response",
author = "S. Rusconi and P. Vitiello and F. Adorni and B. Bruzzone and {De Luca}, A. and V. Micheli and P. Meraviglia and R. Maserati and {Di Pietro}, M. and G. Colao and G. Penco and {Di Biagio}, A. and G. Punzi and L. Monno and M. Zazzi",
year = "2013",
month = "10",
doi = "10.1111/1469-0691.12100",
language = "English",
volume = "19",
pages = "936--942",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier B.V.",
number = "10",

}

TY - JOUR

T1 - Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database

AU - Rusconi, S.

AU - Vitiello, P.

AU - Adorni, F.

AU - Bruzzone, B.

AU - De Luca, A.

AU - Micheli, V.

AU - Meraviglia, P.

AU - Maserati, R.

AU - Di Pietro, M.

AU - Colao, G.

AU - Penco, G.

AU - Di Biagio, A.

AU - Punzi, G.

AU - Monno, L.

AU - Zazzi, M.

PY - 2013/10

Y1 - 2013/10

N2 - Raltegravir (RAL) is the only licensed human immunodeficiency virus (HIV) integrase inhibitor. The factors associated with the virological response to RAL-containing regimens and the prevalence of integrase mutations associated with RAL failure deserve further investigation. From the Antiretroviral Resistance Cohort Analysis database, we selected triple-class-experienced subjects failing their current treatment with complete treatment history available. Selection criteria included HIV-RNA, CD4 count and HIV genotype within 3 months of RAL initiation. Factors associated with 24-week response were analysed; genotypic sensitivity scores (GSS) and weighted-GSS were evaluated. Virological response was achieved in 74.3% of 105 subjects. Mutations associated with RAL failure were detected in 12/24 subjects with an integrase genotype, with the prevalence of Q148H + G140S. Each extra unit of GSS (p 0.05, OR 2.62; 95% CI 1.00-6.87). was found to be a associated with response. Weighted-GSS had borderline statistical significance (p 0.063, OR 2.04; 95% CI 0.96-4.33) When stratifying for different cut-offs (

AB - Raltegravir (RAL) is the only licensed human immunodeficiency virus (HIV) integrase inhibitor. The factors associated with the virological response to RAL-containing regimens and the prevalence of integrase mutations associated with RAL failure deserve further investigation. From the Antiretroviral Resistance Cohort Analysis database, we selected triple-class-experienced subjects failing their current treatment with complete treatment history available. Selection criteria included HIV-RNA, CD4 count and HIV genotype within 3 months of RAL initiation. Factors associated with 24-week response were analysed; genotypic sensitivity scores (GSS) and weighted-GSS were evaluated. Virological response was achieved in 74.3% of 105 subjects. Mutations associated with RAL failure were detected in 12/24 subjects with an integrase genotype, with the prevalence of Q148H + G140S. Each extra unit of GSS (p 0.05, OR 2.62; 95% CI 1.00-6.87). was found to be a associated with response. Weighted-GSS had borderline statistical significance (p 0.063, OR 2.04; 95% CI 0.96-4.33) When stratifying for different cut-offs (

KW - Drug resistance

KW - Genotype

KW - human immunodeficiency virus type 1-1

KW - Raltegravir

KW - Virological response

UR - http://www.scopus.com/inward/record.url?scp=84884730779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884730779&partnerID=8YFLogxK

U2 - 10.1111/1469-0691.12100

DO - 10.1111/1469-0691.12100

M3 - Article

VL - 19

SP - 936

EP - 942

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 10

ER -